- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-11-01-2020
Synthetic Biology and the Environment
November 16, 2020
Sustainability
40
11
SynBio opens new environmental sustainability possibilities for pharma.
Measuring Pharma’s Wider Mandate
November 16, 2020
Features
40
11
Especially critical amid the continuing global pandemic, key metrics are laid out to help life sciences companies define, measure, and effectively communicate sustainability practices and progress—and build foundations for long-term business value.
Patients as the North Star
November 16, 2020
Executive Profile
40
11
Matt Ros, EVP, chief strategy and business officer of Epizyme, talks to Pharm Exec about his career in oncology and his role in transforming an epigenetics R&D company into a fully integrated commercial business.
Going Public During Lockdown: IPO Insights from Five Biotechnology CFOs
November 16, 2020
Features
40
11
Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.
A Rare-Disease Must? Building Long-Term Relationships
November 16, 2020
Features
40
11
The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.
Making Remote Work a Success Beyond COVID
November 16, 2020
Leadership
40
11
How the pandemic helped prove a point.
CRISPR for Diversity, and Humanity’s, Sake
November 16, 2020
From the Editor
40
11
A brief look into how the Gene Editing Institute researching the diversity of responses in African-American regenerative cells to various forms of CRISPR.
Expediting the Cancer Treatment Path
November 16, 2020
Technology
40
11
Following her own experience, a health tech entrepreneur turned to AI to better guide other patients through their treatment journeys.
Vaccine Authorization, Distribution Raise Multiple Challenges
November 16, 2020
Washington Report
40
11
Authorities fear distrust of early preventives and complications for ongoing COVID-19 research.
Pharmaceutical Executive, November 2020 Issue (PDF)
November 16, 2020
Issue PDF
40
11
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
EU Leaders in High-Stakes Gamble on COVID Responses
November 16, 2020
Global Report
40
11
Must maintain trust in face of customary, non-pandemic challenges.
Access & Gene Therapies: Uncertainties Impact Commercial Uptake
November 16, 2020
Features
40
11
A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.
Case Study: A Drug Launch into COVID Headwinds
November 16, 2020
Back Page
40
11
Lessons to launch by during a pandemic—or otherwise.
A Record Year, But Will Recent Valuation Fatigue Continue?
November 16, 2020
Finance
40
11
Biopharma raises an unprecedented $100 billion.
Advancing the Science for Minds: Dr. Husseini Manji, J&J
October 23, 2020
Features
40
11
Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.